Prelude Therapeutics Incorporated
PRLDBiotechnology
$4.10−0.97%As of Oct 29vs prior close
- Market cap
- $326.5M
- P/E (TTM)
- –
- From 52W high
- −38.16%
- EPS (LTM)
- -$0.73
- Revenue (LTM)
- $22.4M
- Net margin
- -269.75%
- Dividend yield
- 0.00%
Nomior Score
47
Steady ProfileBottom 44% of the scored universe
Growth49
Quality37
Value48
Momentum82
Resilience30
Growth
+73.43%revenue a year over 1 fiscal year
YE24 $7MLTM $22.4M
Connections
Revenue to profitQ2 YE26
The operating loss was 271% of revenue.
Who owns it
2funds